Want to see BCDA full AI Analyst Report?
BCDA Stock Chart & Stats
$0.85
-$0.04(-4.92%)
At close: 4:00 PM EDT
$0.85
-$0.04(-4.92%)
Day’s Range― - ―
52-Week Range$0.75 - $2.29
Previous Close$0.82
Volume275.31K
Average Volume (3M)831.61K
Market Cap
$14.39M
Enterprise Value$12.54
Total Cash (Recent Filing)$951.00K
Total Debt (Recent Filing)$412.00K
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding14,884,328
10 Day Avg. Volume300,873
30 Day Avg. Volume831,610
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.12
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.50Price Target Upside1723.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.68
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA PMA Pathway ClarityFormal FDA guidance that a single well-designed pivotal HF II trial can support a PMA materially reduces regulatory uncertainty. This clarity lets management concentrate resources on one pivotal study and align statistical/endpoints planning, improving the odds of a definable approval path and payer engagement.
PMDA Support For Japanese FilingPMDA willingness to accept existing CardiAMP data for Shonin filing speeds Japan market entry and reimbursement discussions. Japan as a reference market can provide an earlier commercial beachhead, post‑market study obligations allow conditional launch while collecting real‑world evidence to support wider approvals.
Statistically Significant Blinded Efficacy DataRobust blinded efficacy signals strengthen the clinical case for CardiAMP, underpinning both regulatory dossiers and physician adoption. Statistically significant imaging and composite outcomes enhance credibility with investigators, payers, and potential partners, supporting durable commercial and partnership discussions.
Bears Say
Zero/limited Revenue And Persistent LossesSustained lack of operating revenue and repeated losses erode shareholder equity and financial flexibility. Negative equity and ongoing operating deficits increase reliance on external capital, raising execution risk and potentially constraining long‑term investment in product commercialization and manufacturing scale-up.
Very Limited Cash Runway; Near-term Funding NeedA sub‑quarter cash position against current burn creates a material financing imperative. Needing near‑term transactions to fund regulatory submissions and trial enrollment elevates dilution and execution risk, and creates conditionality around the company’s ability to meet milestones without disruptive capital raises.
Trial Enrollment And Execution RiskDependence on rapid scale‑up of site activation and patient enrollment creates a durable operational risk to achieving endpoints on schedule. Slow enrollment or resource shortfalls could delay a pivotal readout, extend cash burn, and defer regulatory submissions, undermining the timelines that underlie strategic planning.
BioCardia News
BCDA FAQ
What was Biocardia’s price range in the past 12 months?
Biocardia lowest stock price was $0.75 and its highest was $2.29 in the past 12 months.
What is Biocardia’s market cap?
Biocardia’s market cap is $14.39M.
When is Biocardia’s upcoming earnings report date?
Biocardia’s upcoming earnings report date is Nov 11, 2026 which is in 91 days.
How were Biocardia’s earnings last quarter?
Biocardia released its earnings results on Aug 12, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.05.
Is Biocardia overvalued?
According to Wall Street analysts Biocardia’s price is currently Undervalued.
Does Biocardia pay dividends?
Biocardia does not currently pay dividends.
What is Biocardia’s EPS estimate?
Biocardia’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biocardia have?
Biocardia has 14,884,328 shares outstanding.
What happened to Biocardia’s price movement after its last earnings report?
Biocardia reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -7.339%.
Which hedge fund is a major shareholder of Biocardia?
Currently, no hedge funds are holding shares in BCDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biocardia
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
BCDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong clinical and regulatory progress—statistically significant blinded echocardiography results, constructive PMDA guidance in Japan, favorable FDA engagement, device pathway clarity for Helix, and reduced operating expenses. However, these positives are tempered by an immediate funding shortfall (cash of $951k), the need to complete an additional pivotal trial for U.S. approval (PMA pathway) and enrollment/resource risks for the HF II study. Management plans near-term financing in Q2 to fund the Japan submission and trial enrollment, but execution and funding risk remain material.View all BCDA earnings summariesBCDA Stock 12 Month Forecast
Average Price Target
$15.50
▲(1723.53% Upside)
Technical Analysis
Pluri
―
Celularity
―
Revelation Biosciences
―
SeaStar Medical Holding
―
Cardio Diagnostics Holdings
―
Ownership Overview
14.64% Insiders
1.26% Mutual Funds
<0.01% Other Institutional Investors
83.26% Public Companies and
Individual Investors